The emergence of nitazenes. The co-occurrence of opioid and stimulant use disorders. The proliferation of fentanyl-adulterated counterfeit pills. At every harrowing new turn, the evolving opioid epidemic presents added complexities and urgent clinical challenges. Data show the deadly reach of the epidemic imperils Americans of every demographic and walk of life.
Join Hazelden Betty Ford’s chief medical officer, Alta DeRoo, MD, along with research scientist/clinical psychologist, Quyen Ngo, PhD, and pharmacist/trainer, Kerry Hettinger, PharmD, to examine advanced treatment approaches, consider integrated risk reduction strategies and identify the most-effective overdose prevention measures.
Review epidemiology data and trends on opioid overdoses
Describe the makeup and impact of novel synthetic opioids and counterfeit pills
Discuss the role of risk reduction strategies in overdose prevention
Define clinical approaches to address fentanyl-related treatment, MOUD and recovery challenges
Can't attend on the scheduled date?
Register and you'll receive notice when we post the recording for on-demand viewing.
A certificate of completion will be awarded for attending this event. Please note, this event has not been approved for continuing education (CE) credit. The participant is responsible to verify if this activity meets their continuing education board requirements in order to gain credit.
Alta DeRoo, MD, DFASAM, FACOG
A board certified addiction medicine physician and obstetrician-gynecologist, Dr. DeRoo serves as chief medical officer of the Hazelden Betty Ford Foundation. She joined Hazelden Betty Ford in 2020 as medical director of the Betty Ford Center’s three facilities in California, located in Rancho Mirage, West Los Angeles and San Diego. Dr. DeRoo is a Distinguished Fellow of the American Society of Addiction Medicine and a member of the American Association of Addiction Psychiatry and the American College of Obstetricians and Gynecologists. Her extraordinary record of accomplishment includes a 24-year career in the U.S. Navy.
Quyen Ngo, PhD
A research scientist and clinical psychologist, Dr. Ngo is the executive director of Hazelden Betty Ford Foundation’s Butler Center for Research. She holds a PhD in clinical psychology and women's studies from the University of Michigan in Ann Arbor, where she also completed a post-doctoral research fellowship. Dr. Ngo has conducted grant-funded research on the role of substance use in intimate partner violence and technology-enhanced brief interventions for substance use disorders.
Kerry Hettinger, PharmD
A registered pharmacist in Kentucky and Indiana, Dr. Hettinger is a pharmacotherapy trainer and technical consultant for the Hazelden Betty Ford Foundation. She provides pharmacotherapy education on the disease of addiction and addictive substances to behavioral and medical healthcare professionals across the United States. Dr. Hettinger has authored many presentations in areas focused on the neurobiology and treatment of substance use disorders, psychopharmacology, medications for the treatment of substance use disorders, naloxone education and co-prescribing and opioid stewardship.